Science Corporation implants PRIMA vision chip in first Stargardt disease patient
Overview
Science Corporation says it implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, an inherited eye disease that gradually destroys central vision.
The implant was placed in May during the company's trial at Sydney Eye Hospital in Australia. CEO Max Hodak says the patient read a letter in the first rehabilitation session and a word in the second.
Hodak says the current 2 mm by 2 mm implant gives sharp, high-contrast black-and-white vision in a small central patch. He says a next-generation device is expected in humans within a year.
Written by AI from the articles below · updated Oct 13, 7:29 PM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- TechCrunch · AINewsScience Corporation implants its vision-restoring chip in first Stargardt disease patient
AIScience Corporation says its first Stargardt disease patient received the PRIMA vision-restoring implant in May during a trial at Sydney Eye Hospital in Australia. The patient saw a letter in the first rehabilitation session and read a word in the second. CEO Max Hodak said the current 2 mm by 2 mm implant gives sharp, high-contrast black-and-white vision in a small central patch, and that a next-generation device is expected in humans within a year.
Heat trend
- Current comparable heat
- 9
- Peak comparable heat
- 10Oct 13, 8:00 PM ET
- Change in past 24 hours
- –
The trend compares only continuously observed participants, so its scope may be smaller than the current heat total. Hover or tap for hourly heat; use arrow keys with a keyboard.